Skip to main content
SpringerLink
Log in

Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

The role of DNA repair gene polymorphisms in cancer development, progression, and response to treatment has received increased attention. We conducted a prospective study to determine whether associations exist between two polymorphisms in XRCC1 and ADPRT and the outcomes of Chinese ovarian cancer patients treated with platinum-based chemotherapy. A total of 335 new cases of ovarian cancer were consecutively collected between May 2005 and May 2007. Follow-up lasted for 4 years, and the outcome measure was survival time. Individuals carrying XRCC1 194Trp/Trp had a longer survival time than did those with the Arg/Arg genotype. Similarly, those carrying XRCC1 399 Gln/Gln genotypes had 0.44-fold the risk of death than those with the Arg/Arg genotype. The combination of XRCC1 194 Trp allele and 399 Gln allele could decrease the death risk of ovarian cancer. In summary, this study is the first to evaluate the associations between polymorphisms in DNA repair gene polymorphism and the risk of ovarian cancer in Chinese population. Our study found a significant association between XRCC1 Arg399Gln and XRCC1 Arg194Trp polymorphism and the clinical outcome of ovarian cancer. Furthermore, studies with larger sample sizes are still needed to confirm these associations in Chinese population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ries LAG, Young JL, Keel GE et al (2007) SEER program, NIH Pub. No. 07-6215. National Cancer Institute, Bethesda

    Google Scholar 

  2. Jin F, Shu XO, Devesa SS, Zheng W, Blot WJ, Gao YT (1993) Incidence trends for cancers of the breast, ovary, and corpus uteri in urban Shanghai, 1972–89. Cancer Causes Control 4:355–360. doi:10.1007/bf00051338

    Article  PubMed  CAS  Google Scholar 

  3. Hogberg T, Glimelius B, Nygren P (2001) A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 40:340–360

    Article  PubMed  CAS  Google Scholar 

  4. Qiao Y, Spitz MR, Shen H, Guo Z, Shete S, Hedayati M, Grossman L, Mohrenweiser H, Wei Q (2002) Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 23:295–299. doi:10.1093/carcin/23.2.295

    Article  PubMed  CAS  Google Scholar 

  5. Kudo K, Gavin E, Das S, Amable L, Shevde LA, Reed E (2012) Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum–DNA adduct repair. Oncogene. doi:10.1038/onc.2011.610

  6. Kang J, D’Andrea AD, Kozono D (2012) A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J Natl Cancer Inst 204:670–681

    Article  Google Scholar 

  7. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, de Murcia G (1998) XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 18:3563–3571

    PubMed  CAS  Google Scholar 

  8. Keith WC (2003) XRCC1 and DNA strand break repair. DNA Repair 2:955–969

    Article  Google Scholar 

  9. Takabatake R, Koiwa T, Kasahara M, Takashima K, Futo S, Minegishi Y, Akiyama H, Teshima R, Oguchi T, Mano J, Furui S, Kitta K (2011) Interlaboratory validation of quantitative duplex real-time PCR method for screening analysis of genetically modified maize. Shokuhin Eiseigaku Zasshi 52:265–269. doi:org/10.3358/shokueishi.52.265

  10. Aneiros E, Dabrowski M (2009) Novel temperature activation cell-based assay on thermo-TRP ion channels. J Biomol Screen 14:662–667. doi:10.1177/1087057109336595

    Google Scholar 

  11. Oguchi T, Onishi M, Minegishi Y, Kurosawa Y, Kasahara M, Akiyama H, Teshima R, Futo S, Furui S, Hino A, Kitta K (2009) Development of quantitative duplex real-time PCR method for screening analysis of genetically modified maize. Shokuhin Eiseigaku Zasshi 50:117–125. doi:org/10.3358/shokueishi.50.117

  12. Shirota Y, Stoehlmacher J, Brabender J et al (2001) ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:4298–4304

    PubMed  CAS  Google Scholar 

  13. Britten RA, Liu D, Tessier A, Hutchison MJ, Murray D (2000) ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 89:453–457. doi:10.1002/1097-0215(20000920)89:5<453:AID-IJC9>3.3.CO;2-5

    Article  PubMed  CAS  Google Scholar 

  14. Lord RVN, Brabender J, Gandara D et al (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non small cell lung cancer. Clin Cancer Res 8:2286–2291

    PubMed  CAS  Google Scholar 

  15. Krivak TC, Darcy KM, Tian C et al (2011) Single nucleotide polymorphisms in ERCC1 are associated with disease progression and survival in patients with advanced stage ovarian and primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol 122:121–126. doi:10.1016/j.ygyno.2011.03.027

    Article  PubMed  CAS  Google Scholar 

  16. Brem R, Hall J (2005) XRCC1 is required for DNA single-strand break repair in human cells. Nucleic Acids Res 33:2512–2520. doi:10.1093/nar/gki543

    Article  PubMed  CAS  Google Scholar 

  17. Nazarkina ZK, Khodyreva SN, Marsin S, Lavrik OI, Radicella JP (2007) XRCC1 interactions with base excision repair DNA intermediates. DNA Repair (Amst) 6:254–264. doi:10.1016/j.dnarep.2006.10.002

    Article  CAS  Google Scholar 

  18. Savas S, Kim DY, Ahmad MF, Shariff M, Ozcelik H (2004) Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomarkers Prev 13:801–807

    PubMed  CAS  Google Scholar 

  19. Wu K, Su D, Lin K, Luo J, Au WW (2011) XRCC1 Arg399Gln gene polymorphism and breast cancer risk: a meta-analysis based on case–control studies. Asian Pac J Cancer Prev 12:2237–2243. doi:10.1002/ijc.24446

    PubMed  Google Scholar 

  20. Kiyohara C, Takayama K, Nakanishi Y (2006) Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer 54:267–283. doi:10.1016/j.lungcan.2006.08.009

    Article  PubMed  Google Scholar 

  21. Stern MC, Siegmund KD, Conti DV, Corral R, Haile RW (2006) XRCC1, XRCC3, and XPD polymorphisms as modifiers of the effect of smoking and alcohol on colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 15:2384–2390. doi:10.1158/1055-9965.EPI-06-0381

    Article  PubMed  CAS  Google Scholar 

  22. Huang WY, Chow WH, Rothman N, Lissowska J, Llaca V, Yeager M, Zatonski W, Hayes RB (2005) Selected DNA repair polymorphisms and gastric cancer in Poland. Carcinogenesis 26:1354–1359. doi:10.1093/carcin/bgi084

    Article  PubMed  CAS  Google Scholar 

  23. Hirata H, Hinoda Y, Tanaka Y et al (2007) Polymorphisms of DNA repair genes are risk factors for prostate cancer. Eur J Cancer 43:231–237. doi:10.1016/j.ejca.2006.11.005

    Article  PubMed  CAS  Google Scholar 

  24. Hsieh YY, Chang CC, Chen SY, Chen CP, Lin WH, Tsai FJ (2012) XRCC1 399 Arg-related genotype and allele, but not XRCC1 His107Arg, XRCC1 Trp194Arg, KCNQ2, AT1R, and hOGG1 polymorphisms, are associated with higher susceptibility of endometriosis. Gynecol Endocrinol 28:305–309

    Article  PubMed  CAS  Google Scholar 

  25. Fard-Esfahani P, Fard-Esfahani A, Fayaz S et al (2011) Association of Arg194Trp, Arg280His, and Arg399Gln polymorphisms in X-ray repair cross-complementing group 1 gene and risk of differentiated thyroid carcinoma in Iran. Iran Biomed J 15:73–78

    PubMed  CAS  Google Scholar 

  26. Xu C, Wang X, Zhang Y, Li L (2011) Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non small cell lung cancer. Zhongguo Fei Ai Za Zhi 14:912–917

    PubMed  Google Scholar 

  27. Saadat M, Mohammadynejad P, Ghanizadeh A, Saadat I (2012) Genetic polymorphisms (at codons 194 and 399) in the DNA repair gene XRCC1 and susceptibility to bipolar disorder. Psychiatry Res. doi:10.1016/j.psychres.2012.01.021

  28. Suh KW, Kim JH, Kim do Y, Kim YB, Lee C, Choi S (2006) Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer: the MTHFR or XRCC1 gene? Ann Surg Oncol 13:1379–1385

    Article  PubMed  Google Scholar 

  29. de las Peña R, Sanchez-Ronco M, Alberola V et al (2006) Spanish lung cancer group. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non small cell lung cancer patients. Ann Oncol 17:668–675. doi:10.1093/annonc/mdj135

    Article  Google Scholar 

  30. Bewick MA, Conlon MS, Lafrenie RM (2006) Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol 24:5645–5651. doi:10.1200/jco.2006.05.9923

    Article  PubMed  CAS  Google Scholar 

  31. Wu X, Gu J, Wu TT et al (2006) Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 4:3789–3798. doi:10.1200/JCO.2005.03.6640

    Article  Google Scholar 

  32. Khrunin AV, Moisseev A, Gorbunova V, Limborska S (2010) Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 10:54–61. doi:10.1038/tpj.2009.45

    Article  PubMed  CAS  Google Scholar 

  33. Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS, Kang SB (2009) Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol 113:264–269. doi:10.1016/j.ygyno.2009.01.002

    Article  PubMed  CAS  Google Scholar 

  34. Godoy H, Mhawech-Fauceglia P, Beck A, Miller A, Lele S, Odunsi K (2011) Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome. Int J Gynecol Pathol 30:139–144. doi:10.1097/PGP.0b013e3181fa5a64

    Article  PubMed  Google Scholar 

  35. Huehls AM, Wagner JM, Huntoon CJ, Geng L, Erlichman C, Patel AG, Kaufmann SH, Karnitz LM (2011) Poly(ADP-ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells. Cancer Res 71:4944–4954

    Article  PubMed  CAS  Google Scholar 

  36. Weil MK, Chen AP (2011) PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer 35:7–50. doi:10.1016/j.currproblcancer.2010.12.002

    Article  PubMed  Google Scholar 

  37. Zhang X, Miao X, Liang G, Hao B, Wang Y, Tan W, Li Y, Guo Y, He F, Wei Q, Lin D (2005) Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res 65:722–726

    PubMed  CAS  Google Scholar 

  38. Smith SJ, Long A, Barrow JH, Macarthur DC, Coyle B, Grundy RG, Children’s Cancer and Leukemia Group Biological Studies Committee (2011) Pediatric high-grade glioma: identification of poly(ADP-ribose) polymerase as a potential therapeutic target. Neuro Oncol 13:1171–1177

    Article  PubMed  Google Scholar 

  39. Zhang Z, Miao XP, Tan W, Guo YL, Zhang XM, Lin DX (2006) Correlation of genetic polymorphisms in DNA repair genes ADPRT and XRCC1 to risk of gastric cancer. Chinese J Canc 25:7–10

    Google Scholar 

  40. Smith TR, Liu-Mares W, Van Emburgh BO et al (2011) Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer. Carcinogenesis 32:1354–1360. doi:10.1093/carcin/bgr117

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank the Chinese Medical Sciences University for the great help provided by its staff. This study was supported by the Natural Science Foundation of Tianjin (08JCYBJC05500).

Conflict of Interest

The authors report no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Gynecologic Cancer, Shengjing Hospital of China Medical University, Shenyang, China

    Kai Li & Wusheng Li

Authors
  1. Kai Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wusheng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kai Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, K., Li, W. Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population. Mol Cell Biochem 372, 27–33 (2013). https://doi.org/10.1007/s11010-012-1442-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-012-1442-4

Keywords

Search

Navigation